Shares climbed approximately 2.4–2.7%, touching highs between $163.93 (£120.58) and $164.37 (£120.90) before pulling back to ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

By Sanchayaita Roy and Sukriti Gupta (Reuters) -European shares closed at a four-week high on Wednesday, with banks the ...

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Danish pharmaceutical giant Novo Nordisk has announced a new 800-million-yuan (approximately USD 111.9 million) investment to ...

The miner's shares rallied Tuesday after President Trump said he would impose 50% duties on copper imports, [sending prices for the metal soaring]( ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...